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Introduction
Stevens Johnson syndrome (SJS)was  first described in
1922 by Stevens and Johnson, and is an immunological
disorder characterised by acute blistering of the skin and
involvement of at least any two mucous membranes from
among oral, nasal, ocular, vaginal and urethral.1
Toxic epidermal necrosis (TEN) is a severe form of SJS and
involves more than 30% of body surface area.2 In general
population, SJS and TEN have an annual incidence (new
cases per million people) of 1.2 to 7.0 and 0.4 to 1.2,
respectively; affecting all ages, genders, all ethnic groups
and races.3,4
The pathogenesis of SJS remains unclear. Aetiological
factors include infection, drugs as allopurinol, antibiotics,
anticonvulsants and non-steroidal anti-inflammatory
drugs [NSAIDs], and malignancies. However,
approximately half of the cases are idiopathic.5,6 The
clinical course is typically prolonged even after drug
discontinuation, which remains the mainstay of
treatment.7
SJS causes visual loss as it can lead to corneal damage,
including scarring and vascularisation. In more than half
of the cases, ocular consequences are acute in nature,
occurring with or after the involvement of skin.8
Ocular manifestations of SJS/TEN remain an understudied
research area, especially in South Asian countries,
including Pakistan. This is despite the evidence of a
genetic predisposition to these conditions among South
Asian population partly due to altered drug metabolism.
The current study was planned to enumerate the ocular
manifestations of SJS/TEN among inpatients at a tertiary
care hospital.
Patients and Methods
The retrospective observational descriptive study was
carried out at the Aga Khan University Hospital, Karachi,
and comprised data on age, gender, aetiology and ocular
findings related to patients diagnosed with SJS/TEN
between January 2000 and December 2011. Patients
having history of previous ocular problems were excluded
from the study. A structured proforma was used to record
data on demographics, type and severity of ocular
complications, and aetiology of SJS or TEN. Detailed drug
history was also noted to figure out the relative frequency
of each aetiological agent.
Data was analysed using SPSS 19. Frequencies and
percentages were calculated to describe categorical
variables. Mean and standard deviation (SD) were
computed for quantitative variables such as age. No
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statistical test of significance was used because of the
descriptive nature of study.
Results
A total of 87 patients with SJS/TEN were hospitalised during
the study period and all were included. Among them,
48(55.2%) were males and 39(44.8%) were female. The
mean age of the patients was 33.2±22.2 years and their
median age was 36 years (range: 1 month to 84 years).
The most common aetiology was idiopathic 20(23%)
followed by NSAIDs and anti-epileptics 11(12.6%) each,
fluroquinolones 8(9.2%), anti-malarial drugs 7(8.0%), anti-
gout medication 6(6.9%), penicillin and cephalosporins
5(5.7%) each (Table).
Besides, 84(96.6%) patients had oral mucosal involvement
whereas 45(51.7%) had ocular and 27(31.0%) had genital-
mucosal involvement. Glassroding was performed in
16(18.4%) patients due to minor conjunctival adhesions.
Even after use of lubricants, 2(2.2%) patients developed
longstanding signs and symptoms of dryness and
conjunctival adhesions, leading to an ulcer formation in
1(1.14%). The ulcer resolved leaving a non-central
corneal scar.
Discussion
The study aimed at reviewing the presenting features,
especially ocular complications, of SJS/TEN in a tertiary
care hospital. It found that nearly half the study
population had ocular manifestations.9 Ocular
complications may occur acutely and may even result in
sight-threatening conditions such as corneal
scars/vascularisation. Therefore, it is extremely important
that these patients have regular eye assessment.10
It is important to mention that the management of ocular
complications of SJS has not changed significantly over the
past several decades. The management of acute eye
manifestations usually starts with frequent lubrication of the
eye surface. In our study, glassroding was performed in
nearly 1 in 5 patients to treat conjunctival adhesions. Two
patients developed long-term eye dryness and conjunctival
adhesions which were treated with eye lubricants. 
The differences in the severity of ocular complications at
presentation are possible in different ethnic and racial
groups because of differences in access to care and
genetic differences in drug metabolism.11 Unfortunately,
there is paucity of literature on such aspects of SJS/TEN,
particularly in South East Asia. Eye involvement often is
long-term and sometime sight-threatening.12 In acute
phase, most patients consult a general physician or a
dermatologist. Ophthalmologist is consulted only later
on. Thus a multi-disciplinary team needs to be involved
from the outset to improve both short- and long-term
management. Patient education about possible risks is
also important.
In the current study, the exact aetiology could not be
identified in one-fourth of cases. Most of our cases were
drug-related, the common agents being NSAIDs, anti-
epileptics, fluroquinolones, anti-malarials, anti-gout
medication, penicillin and cephalosporins. Various studies
have shown that drugs are responsible for up to 60% of
SJS cases.11,13
Conclusion
Ocular manifestations of varying severity are frequent in
SJS/TEN and can lead to long-term complications. Timely
management of eye manifestations is important to
reduce the risk of long-term complications. Drugs were
the most common cause in our patients. Further studies
are vital for a better understanding and identification of
the possible aetiological factors.
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